
    
      Women, in fertile age or premenopausal status, presenting symptomatic myomaswere randomly
      assigned to receive 5 or 10 mg of mifepristone for six months.

      The decreasing in the prevalence of symptoms attributable to myomas is an important goal to
      achieve under both treatments. Another goal is to maintain for more than 6 months the
      benefits of the treatment with mifepristone.
    
  